Firefly Neuroscience 3Q 2026: Revenue $647K, EPS ($0.07) — 10-Q Summary
Firefly Neuroscience reported 3Q 2026 revenue of $647K, up 67% YoY, with net loss narrowing to $1.48M. Growth was driven by recurring subscription revenue, while gross margin improved to 81%. Operating expenses decreased, including selling and marketing costs down 27%. The Evoke EEG System is in use at 85+ U.S. clinical sites.
How this was made

The 30-second read
Why it matters
The earnings release provides fresh data on a micro‑cap biotech, offering a potential short‑term trade idea.
Market read
First‑time earnings disclosure for a micro‑cap; may trigger modest price movement.
What to watch
Cash burn and need for further financing could limit upside.
Background
Firefly Neuroscience filed its 10‑Q for Q3 2026, highlighting subscription‑driven revenue growth and cost reductions.
Ticker impact
Firefly Neuroscience reported Q3 2026 revenue of $647K, a 67% YoY increase, and a narrowed net loss.
likely modest upside as market prices in improved margins and lower expenses
Revenue rose sharply and gross margin improved to 81%, indicating better operating leverage for a micro‑cap biotech.
Market effects
Shows strengthening demand for neuro‑diagnostic subscription services.
Limited to U.S. biotech investors.
Minimal beyond niche neuro‑tech segment.
Counterpoint
Despite revenue growth, the company remains loss‑making; investors may stay cautious.
Key entities
- companyFirefly Neuroscience, Inc.
Neuro‑diagnostic device and software provider.



